Compare Jones Lang LaSalle Inc (JLL) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is the larger of the two by market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| JLL | RPRX | |
|---|---|---|
Market Cap | $13.95B | $25.27B |
Volume | 457,462 | 3,671,183 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $63.96 |
52-Week Low | $280.16 | $35.44 |
Typical Hold Time | 71 Days | 1 Days |
Enterprise Value | $16.71B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $299.87, up 1.08% today, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $5.26 exceeding the $4.56 estimate. Revenue grew to $26.12B in 2025, and net income margin improved to 3.64%. Recent news highlights acquisitions and financing deals, such as the $406M Trammell Crow Center financing announced on September 24, 2026.
The outlook is positive, supported by analyst consensus price target of $450.50 and 58.33% buy ratings. Key opportunities include growth in data center operations and proprietary platforms, while risks involve real estate market volatility and competitive pressures. The stock offers value with a P/E of 14.54 and P/S of 0.53, but investors should monitor debt levels and economic cycles.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
